Tuesday, December 22, 2009 12:01:20 AM
In the shorter term, this is an FDA play for Paramax/Retimax distribution in the USA. But in the longer term, this is a company turnaround play. This is about whether Stephen Davis can clean up the previous management’s mess, and bring out the company’s potential.
Demographics could favor long term holders. The population bulge formed by Baby Boomers in the US is reaching the age where glaucoma becomes a concern. The domestic market for ophthalmic treatments in general, and glaucoma treatments in particular, will only grow over the next ten years.
FEATURED CBD Life Sciences, Inc. (CBDL) Reaches Unprecedented Heights With Explosive Growth and Strategic Expansion in 2024 • Oct 8, 2024 8:00 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM
BNCM COMPLETES MERGER WITH DELEX HEALTHCARE • BNCM • Oct 8, 2024 9:54 AM
Unitronix Corp. to Invest $3 Million in USA Unity Coin Project • UTRX • Oct 7, 2024 7:08 AM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM